Which Diabetes Medication Is Better?
Both Mounjaro and Ozempic are FDA-approved for Type 2 diabetes, but they work differently. This guide breaks down the real differences based on clinical data and user experiences.
We've reviewed a wide range of patient-reported experiences with Mounjaro and Ozempic so you can find the answers you need in one place.
Prices re-read November 18, 2026
Mounjaro costs $1,399 every 4 weeks (about $1,515.58 a month) at Physicians Weight Loss Centers, the cheapest verified Mounjaro price among the providers our tracker re-read in the last 36 hours. Ozempic costs $349 every 4 weeks (about $378.08 a month) at NovoCare / Wegovy Direct, the cheapest verified Ozempic price among the providers our tracker re-read in the last 36 hours. Compounded tirzepatide injections start at $129 a month, month to month, at Eden; the cheapest month-to-month prices are $129 at Eden, $129 at Embody and $149 at Lttl among the 41 providers whose tirzepatide prices our tracker re-read in the last 36 hours. Compounded semaglutide injections start at $79 a month, month to month, at Embody; the cheapest month-to-month prices are $79 at Embody, $99 at Eden and $99 at Lttl among the 43 providers whose semaglutide prices our tracker re-read in the last 36 hours. Compounded medication is not FDA-approved. Prices read on each provider's own site on November 18, 2026.
$1,399 every 4 weeks (about $1,515.58 a month)
at Physicians Weight Loss CentersRead on November 17, 2026 at 12:43 UTC on hub.wellsync.com/en-US/pwlc/conditions/weight-loss/weight-loss/drugs
Cheapest verified Mounjaro price, as the provider words it.
$349 every 4 weeks (about $378.08 a month)
at NovoCare / Wegovy DirectRead on November 17, 2026 at 12:39 UTC on novocare.com/pharmacy.html
Cheapest verified Ozempic price, as the provider words it.
Cheapest month-to-month prices, one per provider, ordered by price alone (41 providers re-read).
Cheapest month-to-month prices, one per provider, ordered by price alone (43 providers re-read).
Read by our tracker on each provider’s own site. AllGLP1 may earn a commission if you sign up through a link above; it never changes the prices shown or their order.
Side-by-side comparison of reported experiences
| Feature | Mounjaro | Ozempic | Source Notes |
|---|---|---|---|
| Active Ingredient | Tirzepatide | Semaglutide | Injectable GLP-1/GIP vs GLP-1 only |
| Primary Indication | Type 2 Diabetes | Type 2 Diabetes | Both FDA-approved for T2D |
| HbA1c Reduction | Up to 2.3% | Up to 1.8% | SURPASS-2 head-to-head trial |
| Typical Weight Loss | 15-22% | 12-15% | Clinical trial data in T2D population |
| Cardiovascular Risk | 42% lower MACE risk* | Proven reduction | *Nature Medicine 2025 real-world study |
| Brand Cost | ~$1,060/mo | ~$935/mo | 2026 retail list pricing |
| Medicare 2026 | Coverage expanding | Negotiation candidate | Policy changes effective 2026 |
| Supply Status | Available | Resolved | FDA shortage tracker Jan 2026 |
Injectable GLP-1/GIP vs GLP-1 only
Both FDA-approved for T2D
SURPASS-2 head-to-head trial
Clinical trial data in T2D population
*Nature Medicine 2025 real-world study
2026 retail list pricing
Policy changes effective 2026
FDA shortage tracker Jan 2026
Figures in this table were typed when the page was written and may be out of date; today's verified prices are in the cost box above.
Data from the SURPASS-2 (New England Journal of Medicine)
The SURPASS-2 trial was a landmark head-to-head study that directly compared the efficacy and safety of Mounjaro (tirzepatide) versus Ozempic (semaglutide) 1mg in adults with Type 2 diabetes. This study is the gold standard for comparing these two specific molecules.
| Comparison Metric | Mounjaro | Ozempic |
|---|---|---|
| HbA1c Reduction (%) | -2.30% | -1.86% |
| HbA1c < 7.0% Goal | 92% | 81% |
| HbA1c < 5.7% (Normal) | 51% | 20% |
| Weight Loss (%) | 13.1% | 6.7% |
| Weight Loss (lbs) | 25 lbs | 13 lbs |
"In the SURPASS-2 head-to-head trial, Mounjaro (at all doses) was found to be superior to Ozempic 1mg in both glucose control (HbA1c) and weight loss. Furthermore, real-world data published in Nature Medicine (2025) suggests that tirzepatide may offer up to a 42% lower risk of major adverse cardiovascular events compared to semaglutide in patients with Type 2 diabetes."
Results were statistically significant (p < 0.001) across all primary endpoints.
Latest verification performed January 2026.
Answer these 3 questions to see your best match:
Take our 90-second quiz for personalized provider recommendations ranked by your insurance + budget.
Start QuizPatient-reported side effect patterns
Drawing from patient-reported strategies
Real questions from Mounjaro users
Common questions from Mounjaro users
Not sure which is right for you?
🎯Take Our 2-Minute Quiz